Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Sci's Watchman Gets Positive Medicare Coverage Policy

Executive Summary

CMS granted national coverage for left atrial appendage closure procedures to prevent stroke under more favorable conditions than what the Medicare agency had proposed in November. This is good news for Boston Scientific, which is ramping up marketing of its Watchman device.

You may also be interested in...



Medicare Drops Registry Requirement In ICD Coverage Policy And Adds 'Shared Decision-Making'

The new Medicare coverage policy for implantable cardioverter defibrillators, the first revision since 2005, incorporates MRI-compatible devices, tweaks some of the patient criteria, removes thenational registry requirement, and adds a new requirement for "shared decision-making" prior to implanting an ICD in certain patients so the patients understand their options.

HRS 2017: EBR's Leadless CRT Feasibility; Watchman Registry Data; A Novel AF Ablation Catheter From BW; And More Medtronic CRT Data

Results from "real-world" registries of established devices, along with encouraging early results from novel devices were among the highlights of Heart Rhythm 2017, the annual scientific sessions of the Heart Rhythm Society, held in Chicago May 10-13.

Starts & Stops: Boston Scientific Starts, Stops, And Finishes TAVR Trials

Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions each month. This month's edition includes seven trial-terminations – not as many as last month, but more than usual – for a variety of reasons, including Boston Scientific's suspension of all its trials of the Lotus transcatheter aortic valve due to a manufacturing problem.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT035982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel